These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 26168486

  • 1. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
    Tsunoda T, Ishikura S, Doi K, Iwaihara Y, Hidesima H, Luo H, Hirose Y, Shirasawa S.
    Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
    [Abstract] [Full Text] [Related]

  • 2. Growth Suppression of Human Colorectal Cancer Cells with Mutated KRAS by 3-Deaza-cytarabine in 3D Floating Culture.
    Luo H, Nishi K, Ishikura S, Swain A, Morishige N, Yazaki R, Ohshima T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2018 Jul; 38(7):4247-4256. PubMed ID: 29970558
    [Abstract] [Full Text] [Related]

  • 3. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
    Nishi K, Luo H, Ishikura S, Doi K, Iwaihara Y, Wills L, Baillie GS, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2017 Jul; 37(7):3833-3839. PubMed ID: 28668883
    [Abstract] [Full Text] [Related]

  • 4. Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.
    Hashimoto S, Nagai M, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2021 Aug; 41(8):4061-4070. PubMed ID: 34281875
    [Abstract] [Full Text] [Related]

  • 5. MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS.
    Nishi K, Tsunoda T, Uchida Y, Sueta T, Sawatsubashi M, Yamano T, Hashiguchi Y, Swain A, Shirasawa S, Sakata T.
    Anticancer Res; 2020 Aug; 40(8):4687-4694. PubMed ID: 32727793
    [Abstract] [Full Text] [Related]

  • 6. Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.
    Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Kuroki M, Sasazuki T, Shirasawa S.
    Anticancer Res; 2011 Jul; 31(7):2453-9. PubMed ID: 21873159
    [Abstract] [Full Text] [Related]

  • 7. Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner.
    Yoshida K, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2022 Aug; 42(8):3993-4001. PubMed ID: 35896235
    [Abstract] [Full Text] [Related]

  • 8. Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion.
    Nishi K, Ishikura S, Umebayashi M, Morisaki T, Inozume T, Kinugasa T, Aoki M, Nimura S, Swain A, Yoshida Y, Hasegawa S, Nabeshima K, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2020 Aug; 40(8):4663-4674. PubMed ID: 32727790
    [Abstract] [Full Text] [Related]

  • 9. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model.
    Yoshida Y, Tsunoda T, Doi K, Fujimoto T, Tanaka Y, Ota T, Ogawa M, Matsuzaki H, Kuroki M, Iwasaki A, Shirasawa S.
    Anticancer Res; 2012 Jun; 32(6):2301-8. PubMed ID: 22641666
    [Abstract] [Full Text] [Related]

  • 10. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.
    Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A, Shirasawa S.
    Anticancer Res; 2011 Jul; 31(7):2535-9. PubMed ID: 21873171
    [Abstract] [Full Text] [Related]

  • 11. Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model.
    Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T, Shirasawa S.
    Neoplasia; 2010 May; 12(5):397-404. PubMed ID: 20454511
    [Abstract] [Full Text] [Related]

  • 12. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
    Ota T, Doi K, Fujimoto T, Tanaka Y, Ogawa M, Matsuzaki H, Kuroki M, Miyamoto S, Shirasawa S, Tsunoda T.
    Anticancer Res; 2012 Jun; 32(6):2271-5. PubMed ID: 22641662
    [Abstract] [Full Text] [Related]

  • 13. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
    Li Y, Wang J, Gao X, Han W, Zheng Y, Xu H, Zhang C, He Q, Zhang L, Li Z, Zhou D.
    PLoS One; 2014 Jun; 9(11):e113186. PubMed ID: 25427200
    [Abstract] [Full Text] [Related]

  • 14. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
    Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB.
    Cancer Res; 2010 Sep 15; 70(18):7253-63. PubMed ID: 20823162
    [Abstract] [Full Text] [Related]

  • 15. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM.
    Ann Surg Oncol; 2015 Dec 15; 22(13):4158-65. PubMed ID: 26077912
    [Abstract] [Full Text] [Related]

  • 16. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.
    Cancer Res; 2011 Mar 01; 71(5):1520-5. PubMed ID: 21193546
    [Abstract] [Full Text] [Related]

  • 17. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
    Ju B, Chen W, Orr BA, Spitsbergen JM, Jia S, Eden CJ, Henson HE, Taylor MR.
    Mol Cancer; 2015 Feb 03; 14(1):18. PubMed ID: 25644510
    [Abstract] [Full Text] [Related]

  • 18. A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.
    Okamoto H, Matsukawa T, Doi S, Tsunoda T, Sawata Y, Naemura M, Ohnuki K, Shirasawa S, Kotake Y.
    Mol Cell Biochem; 2018 May 03; 442(1-2):39-45. PubMed ID: 28936721
    [Abstract] [Full Text] [Related]

  • 19. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, Troncone G.
    J Clin Pathol; 2015 Apr 03; 68(4):265-9. PubMed ID: 25609577
    [Abstract] [Full Text] [Related]

  • 20. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation.
    Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, Shirasawa S, Tsunoda T, Ueffing M, Xie J, Xin J, Wang X, Proud CG, Boldt K, Al-Khalili Szigyarto C, Kolch W, Lynn DJ.
    Br J Cancer; 2019 Jul 03; 121(1):37-50. PubMed ID: 31133691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.